These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11705534)

  • 1. Dosing regimen of reteplase and costeffectiveness.
    Hödl R; Kraxner W; Maier R; Klein W
    Lancet; 2001 Oct; 358(9291):1462. PubMed ID: 11705534
    [No Abstract]   [Full Text] [Related]  

  • 2. [The FINESSE trial].
    Petronio AS; Piscione F
    G Ital Cardiol (Rome); 2009 Jan; 10(1):1-5. PubMed ID: 19292014
    [No Abstract]   [Full Text] [Related]  

  • 3. Abciximab combined with half-dose reteplase has beneficial effects on inflammatory myocardial response in patients with myocardial infarction.
    Szabo S; Etzel D; Walter T; Kazmaier S; Oikonomopoulos T; Marx R; Hoffmeister HM
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):129-33. PubMed ID: 19786940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
    Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catheter-directed thrombolytic therapy in peripheral artery occlusions: combining reteplase and abciximab.
    Drescher P; McGuckin J; Rilling WS; Crain MR
    AJR Am J Roentgenol; 2003 May; 180(5):1385-91. PubMed ID: 12704056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.
    Nallamothu BK; Bates ER; Hochman JS; Granger CB; Guetta V; Wilcox RG; White HD; Armstrong PW; Savonitto S; Jia G; Lincoff AM; Topol EJ;
    Eur Heart J; 2005 Aug; 26(15):1506-12. PubMed ID: 15800019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
    Merlini PA; Repetto A; Andreoli AM; Ricci S; Lombardi A; Finardi A; Dipasquale G; Lamponi M; Mannucci PM; Ardissino D
    Am J Cardiol; 2004 Jan; 93(2):195-8. PubMed ID: 14715345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
    Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
    J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefical effects of reteplase in combination with abciximab: platelet/leukocyte interactions and coagulation system.
    Szabo S; Walter T; Etzel D; Ehlers R; Kazmaier S; Beyer ME; Hoffmeister HM
    Int J Clin Pharmacol Res; 2003; 23(2-3):37-40. PubMed ID: 15018016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased fibrin specificity and reduced paradoxical thrombin activation of the combined thrombolytic regimen with reteplase and abciximab versus standard reteplase thrombolysis.
    Szabo S; Etzel D; Ehlers R; Walter T; Kazmaier S; Helber U; Beyer ME; Hoffmeister HM
    Drugs Exp Clin Res; 2004; 30(2):47-54. PubMed ID: 15272642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology.
    Benenati J; Shlansky-Goldberg R; Meglin A; Seidl E;
    J Vasc Interv Radiol; 2001 Jul; 12(7):795-805. PubMed ID: 11435535
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
    Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E
    Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Too much, too little, or none at all: dealing with substandard and fake drugs.
    Wan Po AL
    Lancet; 2001 Jun; 357(9272):1904. PubMed ID: 11425409
    [No Abstract]   [Full Text] [Related]  

  • 14. PCI at non-PCI centres: immediate or rescue?
    Danchin N; Armstrong PW
    Lancet; 2008 Feb; 371(9612):534-6. PubMed ID: 18280311
    [No Abstract]   [Full Text] [Related]  

  • 15. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial.
    Di Mario C; Dudek D; Piscione F; Mielecki W; Savonitto S; Murena E; Dimopoulos K; Manari A; Gaspardone A; Ochala A; Zmudka K; Bolognese L; Steg PG; Flather M;
    Lancet; 2008 Feb; 371(9612):559-68. PubMed ID: 18280326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confusion in reperfusion.
    Gibson CM
    J Am Coll Cardiol; 2003 Oct; 42(7):1186-7. PubMed ID: 14522477
    [No Abstract]   [Full Text] [Related]  

  • 18. Does thrombolytic therapy facilitate or foil primary PCI?
    Leopold JA
    N Engl J Med; 2008 May; 358(21):2277-9. PubMed ID: 18499572
    [No Abstract]   [Full Text] [Related]  

  • 19. Facilitated percutaneous intervention following combination therapy with reteplase and abciximab for acute myocardial infarction.
    Weinstock BS
    J Invasive Cardiol; 2002 Feb; 14(2):100-4; quiz 104-5. PubMed ID: 11818648
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
    Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
    Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.